WilsonHCG Recognized as a “Leader” in NelsonHall’s 2019 NEAT Vendor Evaluation for All RPO Categories
WilsonHCG has been identified as a “Leader” in NelsonHall’s NEAT Vendor Evaluation for RPO. The global talent solutions provider was recognized as a leader in all categories that were evaluated, including overall, candidate experience, geographic footprint & scalability, services delivery innovation, sourcing candidates and technology innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190717005385/en/
This chart shows WilsonHCG's position against other RPO providers for "Candidate Experience." Identified as a "Leader" in "Candidate Experience," this recognizes the company's ability to meet future client requirements as well as deliver immediate benefits to RPO clients with a specific focus on candidate experience. (Graphic: Business Wire)
Nikki Edwards, Principal HR Services Research Analyst at NelsonHall, said: “WilsonHCG’s proactive, innovative partnership approach is embedded in its culture. These strengths can be seen in its talent acquisition initiatives and are consistently highlighted as stand-out features by its clients.”
John Wilson, CEO at WilsonHCG, attributes being named a leader in all categories to its innovative approach. “This continual recognition is a result of the hard work and passion our people display every day. We are proud to rank as an overall RPO leader as well as our extremely strong showing related to candidate experience and service delivery innovation. We strive for excellence to help our clients exceed their talent and business goals,” he added.
NelsonHall's RPO NEAT Vendor Evaluation analyzes the performance of vendors offering RPO services. The NEAT tool allows strategic HR decision-makers to assess the capability of vendors across a range of criteria and business situations and identify the best performing vendors overall.
This recognition follows an exciting 12 months for WilsonHCG. The global talent solutions leader expanded into new markets and countries, was the only RPO provider to be named a “Star Performer” in Everest Group’s RPO Service Provider PEAK Matrix™ Assessment for the sixth year in a row and was recognized as a top global RPO provider in HRO Today Baker's Dozen for the eighth consecutive year.
Learn more here.
About WilsonHCG
WilsonHCG is an award-winning, global leader in total talent solutions. Operating as a strategic partner, it helps companies build modern workforce programs. With a global presence spanning more than 40 countries and six continents, WilsonHCG provides a full suite of configurable talent services including recruitment process outsourcing (RPO), executive search, contingent talent solutions, and technology advisory.
Better People, Better Business.®
About NelsonHall
NelsonHall is the leading global analyst firm dedicated to helping organizations understand the 'art of the possible' in IT and business services. NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors (including NEAT assessments) that helps them make fast and highly informed sourcing decisions. And for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall’s research is based on rigorous, all-original research, and is widely respected for the quality, depth, and insight of its analysis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190717005385/en/
Contact information
Kirsty Hewitt
+44 7889901517
813-418-4479
kirsty.hewitt@wilsonhcg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines13.11.2025 08:00:00 EET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used to: Advance the ongoing Phase I clinical trial of V-212, with topline results expected in Q1 2026. Prepare for a planned Phase Ib combination trial evaluating V-212 with an approved pneumococcal conjugate vaccine (PCV). Complete OPK assay validation to support immunogenicity and functional data read-outs. Implement platform enhancements to the company’s proprietary Synthetic Virus-Like Particle (SVLP) technology. Progress next-generation serotype-independent pneumococcal vaccine programs toward preclinical development. “This financing demonstrates the continued confidence and co
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 06:00:00 EET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 05:00:00 EET | Press release
DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem. The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom